Biologic Therapy
‘Proactive education’ critical to preparing patients for likely biosimilar switch
DENVER — Proactively educating patients on biosimilar efficacy and cost-savings associated with their use can help reduce anxiety and bias if/when their insurance opts to switch, according to a presenter at the Crohn’s and Colitis Congress.
Tezepelumab only biologic to consistently reduce exacerbations in severe allergic asthma
LOUISVILLE, Ky. — Of approved biologics for severe, allergic asthma, tezepelumab was the only one to consistently reduce the annualized exacerbation rate across patient subgroups, according to a literature review.
Predictive models help identify best biologic treatments for psoriasis
Gradient-boosted decision trees and logistic regression were effective in identifying the optimal biologic therapy for psoriasis patients, according to a study.
Biologic therapy for atopic disease appears safe during pregnancy, more research needed
The use of biologics to treat atopic disease before and during pregnancy does not seem to negatively affect maternal or fetal outcomes, according to a review published in The Journal of Allergy and Clinical Immunology: In Practice.
Addressing potential long-term care needs of patients with pediatric psoriasis
Healio spoke with Joy Wan, MD, MSCE, pediatric dermatologist at Johns Hopkins University, about challenges in pediatric psoriasis, collaborative care and available treatment options.
Eosinophilic chronic rhinosinusitis, younger age factors linked to switching asthma biologics
The presence of eosinophilic chronic rhinosinusitis and younger age were identified as factors associated with switching biologic therapies among patients with asthma in a new study published in the Journal of Asthma and Allergy.
Starting Entyvio within ‘30 days of diagnosis’ improved treatment response in UC
Patients with ulcerative colitis were more likely to respond to therapy if started on Entyvio within 30 days of diagnosis rather than if delayed by other initial treatments, according to a presenter at the Crohn’s and Colitis Congress.
Histologic activity not linked to recurrence in postoperative Crohn’s disease
Sexual dysfunction in IBD improved with biologic therapy
Patients with inflammatory bowel disease who responded to biologic therapy experienced improvement in sexual dysfunction, according to research presented at the ACG Annual Scientific Meeting.
Biologic therapy, small molecules induce remission in ulcerative colitis
Compared with placebo, most biologic and small molecule therapies correlated with superiority for the induction of remission in moderate to severe ulcerative colitis, according to research published in Gut.